Roche's Perjeta has been launched today in the UK for use in women with HER2-positive breast cancer before surgery – but, as with many new cancer drugs, access to treatment is uncertain.
The SMC issued a green light for use by NHS Scotland of Roche’s Perjeta (pertuzumab) as an adjuvant (post-surgery) treatment to prevent relapse in patients with HER2-positive early-stage breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback